Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CSCO stock price vs CI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CI's multiple
Needs CI P/E.
Implied fair value · at CSCO's multiple
Needs CSCO P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CISCO SYSTEMS, INC. · implied price per share
Bear
$32.30
Base
$38.62
Bull
$46.85
The Cigna Group · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CIENA CORP
CSCO vs CIEN
Palo Alto Networks Inc
CSCO vs PANW
JUNIPER NETWORKS INC
CSCO vs JNPR
Fortinet, Inc.
CSCO vs FTNT
Arista Networks, Inc.
CSCO vs ANET
Leidos Holdings, Inc.
CSCO vs LDOS
UNITEDHEALTH GROUP INC
CSCO vs UNH
CVS HEALTH Corp
CSCO vs CVS
HUMANA INC
CSCO vs HUM
CENTENE CORP
CSCO vs CNC
WEST PHARMACEUTICAL SERVICES INC
CSCO vs WST
BAXTER INTERNATIONAL INC
CSCO vs BAX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CSCO can sustain its premium multiple despite only 5.3% revenue growth and a DCF range of $23.53-$31.84, then hold or add selectively; otherwise, the data support trimming exposure because the current price of $122.64 implies a very large downside versus intrinsic value estimates.
CSCO trades at a large premium to CI on earnings, sales, and EBITDA metrics despite slower growth. The provided DCF range of $23.53-$31.84 implies the current price of $122.64 is far above intrinsic value estimates, while the historical band suggests CSCO is also above its normal trading range.
Supporting Metrics
